1. Male or female, 18-45 years old, inclusive;

2. BMI: 20.0 to 30.0 kg/m2 , body weight: ≥50.0kg.

3. Ability and willingness to participate in the study, give written informed consent, and comply with the study requirements and all protocol procedures.

1. Presence of clinically significant conditions (including but not limited to respiratory system, cardiovascular system, gastrointestinal system, endocrine system, immune system, integumentary system, nervous system, ENT or other related diseases);

2. History of allergic diseases including asthma, urticaria or eczema, or history of sensitivity to GLP-1 products, digoxin, warfarin, rosuvastatin or metformin;

3. Known difficulty in swallowing tablets or history of gastrointestinal diseases affecting drug absorption;

4. History of receiving any procedures that might affect drug absorption, distribution, metabolism or excretion;

5. History of acute or chronic pancreatitis;

6. History of documented or suspected hypoglycemic episodes within 6 months prior to screening;